![]() |
|
|
Vol. 28, Issue 10, 1255-1261, October 2000
Hybridon, Inc., Milford, Massachusetts
The ocular disposition and toxicity of GEM132, a mixed backbone
phosphorothioate oligonucleotide developed for the treatment of
cytomegalovirus-induced retinitis, were studied in rabbits for 6 months
following single intravitreal injection of 5, 20, or 100 µg/eye
(toxicity) and 3.7, 15.7, or 78.5 µg/eye (disposition). Intraocular
pressure, electroretinograms, and ophthalmoscopy were evaluated in the
toxicity arm as well as gross and microscopic pathology at the
termination of the study. Vitreous humor, retina, and the remaining
ocular tissues were collected from all animals in the disposition arm.
No toxicities were observed in the low-dose group. Intraocular pressure
was transiently mildly increased in the mid- and high-dose groups;
macroscopic findings were mild and infrequent. Changes in
electroretinograms and histopathological findings attributed to GEM132
were observed by 4 weeks postdose in the high-dose group. Area under
the curve values in all ocular tissues sampled were proportional
to dose, suggesting GEM132 disposition exhibited first-order kinetics.
Vitreous humor concentrations decreased in a multiphasic manner,
consistent with rapid distribution. Polyacrylamide gel
electrophoresis analysis of retinal extracts indicated that, at
4 weeks postdose, 90% of the radioactivity was associated with parent
compound. At 8 weeks postdose, this had decreased to 70%, and
subsequently to 50% at 21 weeks postdose. In retina, GEM132 reached
concentrations >5 times IC90 by 1 week postdose, with
maximum concentrations 4 to 8 weeks postdose. Retinal concentrations of
intact GEM132 then declined at a very slow rate. Microautoradiography
suggested that radioactivity was distributed throughout the retinal
layers, the largest amount being located in the middle layers.